DNAtrix is a privately held, clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. An Alumni of the JLabs SanDiego. and having very limited SBIR Involvement, in 2012 DNAtrix had merged/acquired another SBIR firm, Vectorlogics of Birmingham, AL. Viruses are understood to be good at killing cells. Hence scientists have harnessed this ability by modifying a common cold virus so that it targets and kills cancer cells selectively. The Companys lead product, DNX-2401, had been the culmination of more than a decade of scientific and clinical research and proved to be the most potent and effective oncolytic virus delivered to human brain tumors to that point. DNAtrix's oncolytic viruses initiate a chain reaction of tumor cell killing by selectively replicating within cancer cells (but not normal cells), triggering an immune response directed against tumors. DNAtrix has multiple virus candidates in clinical trials for cancers with urgent need for novel approaches. DNAtrixs oncolytic viruses initiate a chain reaction of tumor cell killing by selectively replicating within cancer cells (but not normal cells), triggering an immune response directed against tumors. DNAtrix has multiple virus candidates in clinical trials for cancers with urgent need for novel approaches.
